• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025

    10/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email

    BOSTON, Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, November 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 6, 2025.

    The call can be accessed via teleconference at: Q2 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

    A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/6q36mw7d

    A replay of the conference call and webcast will be available for one year beginning on November 6, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.

    ABOUT HAEMONETICS

    Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

    Investor Contacts:



    Olga Guyette, Vice President-Investor Relations & Treasury          

    David Trenk, Manager-Investor Relations

    (781) 356-9763

    (203) 733-4987

    olga.guyette@haemonetics.com

    david.trenk@haemonetics.com

     

    Media Contact:



    Josh Gitelson, Sr. Director-Global Communications



    (781) 356-9776



    josh.gitelson@haemonetics.com



    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-second-quarter-fiscal-year-2026-results-november-6-2025-302580124.html

    SOURCE Haemonetics Corporation

    Get the next $HAE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    5/22/2026$80.00Neutral → Buy
    BofA Securities
    5/12/2026$94.00 → $89.00Outperform
    Barrington Research
    12/15/2025Buy → Hold
    Needham
    12/11/2025$88.00Buy → Neutral
    Citigroup
    8/11/2025$78.00Strong Buy → Outperform
    Raymond James
    8/8/2025$62.00Overweight → Neutral
    Analyst
    8/8/2025$95.00 → $86.00Outperform
    Barrington Research
    7/9/2025$90.00Neutral → Buy
    Citigroup
    More analyst ratings

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haemonetics upgraded by BofA Securities with a new price target

    BofA Securities upgraded Haemonetics from Neutral to Buy and set a new price target of $80.00

    5/22/26 8:18:54 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Haemonetics with a new price target

    Barrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $89.00 from $94.00 previously

    5/12/26 8:01:51 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics downgraded by Needham

    Needham downgraded Haemonetics from Buy to Hold

    12/15/25 9:55:33 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

    BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.ABOUT HAEMONETICSHaemonetics is a global medical technology co

    6/2/26 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible onlineBOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026.Conference Call and Webcast Information:Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event

    5/7/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics to Present at Bank of America 2026 Healthcare Conference

    BOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of America 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:00 a.m. PT.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/75d0U1.cfm.A replay of the recorded webcast will become accessible within 24 hours after the event and will be available for one year on Haemonetics' Investor Relations website.ABOUT HAEMONETICSHaemonetics is a global medical technology company dedicated to

    5/5/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kroll Mark W bought $98,784 worth of shares (1,400 units at $70.56), increasing direct ownership by 6% to 24,757 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    11/12/25 4:18:34 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    5/19/26 5:37:56 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    EVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    5/19/26 5:36:33 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 2,505 shares and was granted 29,312 shares, increasing direct ownership by 97% to 54,444 units (SEC Form 4) (for withholding tax)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    5/19/26 5:34:54 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    SEC Filings

    View All

    SEC Form SD filed by Haemonetics Corporation

    SD - HAEMONETICS CORP (0000313143) (Filer)

    5/28/26 4:15:02 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Haemonetics Corporation

    10-K - HAEMONETICS CORP (0000313143) (Filer)

    5/20/26 6:31:33 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    5/7/26 6:02:40 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

    BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

    10/4/22 6:51:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Financials

    Live finance-specific insights

    View All

    Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible onlineBOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026.Conference Call and Webcast Information:Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event

    5/7/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026

    BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026. The call can be accessed via teleconference at: Q4 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While n

    4/1/26 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registra

    2/5/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/12/24 12:54:20 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/8/24 10:41:07 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care